Plasma cell myeloma
Not recruitingStudy on the Safety and Effects of Belantamab Mafodotin with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Study on the Safety and Effects of Belantamab Mafodotin with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Disease:Plasma cell myeloma
- Substances:Belantamab MafodotinDexamethasone+1
Greece- Participants:18–64 years · 65+ years
- Substances:Belantamab Mafodotin
- Sponsor:Hellenic Society Of Hematology












